<DOC>
	<DOCNO>NCT00181935</DOCNO>
	<brief_summary>The objective study study safety , effectiveness , tolerability dose regimen risperidone , olanzapine , treatment mania Bipolar Disorder I Bipolar II Disorder preschool child 8 week period . We hypothesize atypical neuroleptic may effective treat pediatric mania , low risk extrapyramidal side effect .</brief_summary>
	<brief_title>Risperidone Versus Olanzapine Mania Preschool Children 4 6 Years Age With Bipolar Disorder</brief_title>
	<detailed_description>Risperidone olanzapine atypical neuroleptic market treatment psychotic disorder adult . These medicine call atypical neuroleptic unique pharmacological profile , include D2 5HT2 antagonistic effect . The combined dopaminergic serotonergic activity seem associate antipsychotic effect , also mood stabilizing , mood elevate tardive dyskinesia . The anti-climactic effect class drug lead recent FDA approval olanzapine monotherapy adult bipolar disorder . The study consist 8 week , open-label treatment period random assignment two determined treatment arm , risperidone olanzapine . We plan enroll 5 subject arm . During 8 week treatment , patient see weekly interval receive study medication . At week , measure safety efficacy obtain . Two team clinician see patient visit . Team 1 treat team , adjust medication dosage determine safety continuation study patient . Team 2 blind randomization status patient assess clinical improvement use efficacy measure . For patient complete 8-week acute phase without adverse event respond medication assign allow take part additional 8-week trial medication . At end 8 week , patient respond assigned treatment eligible enrol invited participate separate10 month continuation study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Male female patient , 46 year age . 2 . Parent legal representative must level understanding sufficient communicate intelligently investigator study coordinator , cooperate test examination require protocol . 3 . Patients legal representative must consider reliable . 4 . Each patient his/her authorized legal representative must understand nature study . The patient 's authorized legal representative must sign informed consent document . 5 . Patient must diagnosis bipolar I bipolar II disorder currently display acute manic , hypomanic , mixed episode ( without psychotic feature ) accord DSMIV base clinical assessment confirm structured diagnostic interview ( Kidd Schedule Affective Disorders ) . 6 . Patients must initial score YMRS total score least 15 . 7 . Patient must able participate mandatory blood draw . 1 . Investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild . 2 . Serious , unstable illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease 3 . Uncorrected hypothyroidism hyperthyroidism . 4 . History severe allergy multiple adverse drug reaction . 5 . Nonfebrile seizure without clear resolve etiology . 6 . Leukopenia history leukopenia without clear resolve etiology . 7 . Judged clinically serious suicidal risk . 8 . Any concomitant medication primarily central nervous system activity specify Concomitant Medication portion protocol 9 . History intolerance nonresponder risperidone , olanzapine determine principal investigator . 10 . Treatment nonreversible monoamine oxidase inhibitor within 2 week prior Visit 2 . 11 . Current diagnosis schizophrenia .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>preschooler</keyword>
	<keyword>risperdal</keyword>
	<keyword>zyprexa</keyword>
</DOC>